Skip to main content
Home > BioCentury on BioBusiness > Finance/Investment

Chronological Index of : Finance

 Current Issue
  • Getting industrial

    Why Second Genome tapped an industrial biotech CEO to create products

    Ebb & Flow Getting industrial Second Genome Inc. hired a new president and CEO who is returning to the drug discovery game after spending much of the last 20 years coaxing products from industrial biotech platforms…

    Published on 7/25/2016
  • Leverage over genes

    Why Third Rock, Fulcrum say the time is ripe for a broader approach to gene control

    Ebb & Flow Leverage over genes The decision to invest $55 million in a series A round for Fulcrum Therapeutics Inc. reflects Third Rock Ventures' belief that research tools including induced pluripotent stem cells,…

    Published on 7/25/2016
  • Meeting of the microbiomes

    Behind Flagship's decision to merge two immuno-microbiome portfolio companies

    Ebb & Flow Meeting of the microbiomes When Flagship Ventures created two immuno-microbiome companies two years ago, the biology was so new that the firm didn't fully know what it had. Now, Flagship is merging …

    Published on 7/18/2016
  • Figure: Money Raised in 2016

    Euronext's gene therapy debut Money Raised in 2016 Last week, the biotech industry raised $484 million, bringing to $19 billion the total raised year-to-date. In 2015, a total of $108.8 billion was raised, …

    Published on 7/18/2016
  • Table: Earnings on deck

    Euronext's gene therapy debut Earnings on deck At least eight biotechs and pharmas are expected to report earnings this week. (A) Core EPS for 1H15; (B) Fiscal 1Q Company Date Pre/post mkt 2Q16 EPS est 2Q15 …

    Published on 7/18/2016
  • Euronext's gene therapy debut

    How scarcity value helped gene therapy play GenSight go public on Euronext

    Ebb & Flow Ebb & Flow Euronext's gene therapy debut Table: Earnings on deck Figure: Money Raised in 2016 GenSight Biologics S.A. (Euronext:SIGHT) got out on Euronext thanks in part to investors wanting to own …

    Published on 7/18/2016
  • No ripple effect

    Why a Japanese generics and biosimilars deal had no effect on Japan's biotechs

    Ebb & Flow No ripple effect In contrast to big swings that occur on innovator partnering news, BioCentury's equal price-weighted index of 34 Japanese biotechs did precious little after Nichi-Iko Pharmaceutical Co. …

    Published on 7/18/2016
  • Shedding red

    Biotech winners, losers in 2Q16

    Brexit soured what looked to be a rebound quarter for biotech.

    Published on 7/11/2016
  • Figure: Biotech fund flows

    Ground up Biotech fund flows Biotech funds have seen net outflows in every month of 2016, though the outflow of $933.3 million in 2Q16 was less than either of the first two months of the year. In 1H15, fund …

    Published on 7/11/2016
  • Table: Follow-on performance

    Ground up Follow-on performance Thirty-seven biotechs raised a combined $2.1 billion in follow-ons last quarter, bringing the total for 1H16 to $3.9 billion. In 1H15, 150 companies raised $19 billion. The 2Q16 …

    Published on 7/11/2016
  • Table: IPO performance

    Ground up IPO performance Sixteen biotechs raised $767.5 million in IPOs last quarter, bringing the total raised in 1H16 to $1.4 billion. In 1H15, there were 50 biotech IPOs that raised a total of $5 billion. The …

    Published on 7/11/2016
  • Table: IPO queue

    Ground up IPO queue At least eight companies have announced plans to go public since the start of 2Q16, bringing the IPO queue to at least 23. Unless noted, companies are seeking to list on NASDAQ. Filings are …

    Published on 7/11/2016
  • Ground up

    How biotech stocks may navigate post-Brexit, pre-election waters

    Biotech stocks are shaking off a Brexit hangover while facing a presidential election overhang. Both have curbed generalists' appetite for risk.

    Published on 7/11/2016
  • Rethinking risk

    Investors' top names and milestones in 3Q16

    Going into 2H16, some buysiders want companies that have turned over their data cards. Others are combing a plethora of Phase II and III events for upside.

    Published on 7/11/2016
  • Advising Israel

    New Israel Biotech Fund leverages experienced advisory board for investments

    Ebb & Flow Advising Israel A new Israeli VC fund is leveraging a broad base of biopharma advisers to give its portfolio companies an advantage in development, partnering and commercialization activities. Israel …

    Published on 7/11/2016
  • Figure: London vs. Europe

    Shedding red London vs. Europe The BioCentury Europe index rose 9% in 2Q16, as 10 of 19 continental European companies in the market cap-weighted index showed gains. The big driver was Genmab A/S (CSE:GEN), which …

    Published on 7/11/2016
  • Figure: Price-to-earnings: BT vs. RX

    Shedding red Price-to-earnings: BT vs. RX Biotech's average P/E ended 2Q at 24, up 16% from 1Q16 and down 8% from a year ago. The 2Q16 average is inflated by Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). Backing out …

    Published on 7/11/2016
  • Figure: Results by market cap

    Shedding red Results by market cap Companies in the $1-$4.9 billion market cap segment were the best performing band in 2Q, finishing the quarter up a median of 1.9%. The $500-$999 million segment and those valued…

    Published on 7/11/2016
  • Table: 2Q approvals

    Shedding red 2Q approvals Selected 2Q approvals. Company Approval AbbVie Inc. (NYSE:ABBV) / Genentech Inc. / Roche (SIX:ROG; OTCQX:RHHBY) FDA grants accelerated approval to Venclexta venetoclax to treat …

    Published on 7/11/2016
  • Table: 3Q milestones

    Rethinking risk 3Q milestones Selected products with clinical or regulatory milestones expected in 3Q16. (A) Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is acquiring Celator Pharmaceuticals Inc. (NASDAQ:CPXX); Source: …

    Published on 7/11/2016
  • Table: Index performance

    Shedding red Index performance Index 2Q16 1H16 BioCentury Europe 9% -3% NYSE Arca Pharmaceutical 7% -2% BioCentury London 7% -1% NYSE Arca Biotechnology 2% -21% S&P 500 2% 3% BioCentury 100 2% -…

    Published on 7/11/2016
  • Table: Restructuring watch

    Shedding red Restructuring watch At least 13 companies reported workforce reductions in the second quarter compared to at least five in the same period last year. Table below is sorted by date ascending. All cash …

    Published on 7/11/2016
  • Why Tesaro went NOVA

    Why 'best case scenario' boosts Tesaro on PARP data

    Ebb & Flow Ebb & Flow Why Tesaro went NOVA Figure: Money Raised in 2016 Box: The Score from Greece Even though one marketed PARP inhibitor already has demonstrated that its mechanism works as maintenance …

    Published on 7/11/2016
  • Esperion's LDL-C hangover

    Why Esperion fell again on FDA's lack of committal to LDL-C

    Ebb & Flow Esperion's LDL-C hangover The fall of Esperion Therapeutics Inc. (NASDAQ:ESPR) continued last month as FDA's refusal to commit to LDL-C lowering as an approvable surrogate endpoint for the company's …

    Published on 7/11/2016
  • Box: The Score from Greece

    Why Tesaro went NOVA The Score from Greece Greek Hero finds his Chimera — microbiologist-football professional leads Hellenic onslaught against all comers. U.S. tries Dream Team gambit to no avail. Aging U.K. …

    Published on 7/11/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993